相关实验视频

Updated: Jun 27, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

针对LRP6:癌症治疗的新策略

Wei Xue¹, Bo Zhu², Kaili Zhao³

¹Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, Guangxi Key Laboratory of Research and Evaluation of Bioactive Molecules&College of Pharmacy, Guangxi Medical University, Nanning 530021, China; Department of Pharmacy, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.

Pharmacological research

|May 6, 2024

概括

低密度脂蛋白受体相关蛋白6 (LRP6) 是瘤生长和耐药性的关键驱动因素. 这一审查详细介绍了LRP6的细节.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

Wnt信号通路对细胞过程至关重要,其失调有助于癌症.
低密度脂蛋白受体相关蛋白6 (LRP6) 是Wnt通路中的关键共受体,在各种癌症中经常过度表达.
过度表达LRP6驱动瘤的进展,并与癌症抗药性有关.

研究的目的:

提供LRP6功能和癌症病原发生中的分子机制的全面审查.
探索针对LRP6进行癌症治疗的多种治疗策略.
与Wnt抑制剂相比,讨论LRP6抑制剂的挑战和优势,并审查临床试验进展.

主要方法:

关于LRP6研究近期突破的文献综述.
对LRP6在癌症发展和耐药性方面的作用的分析.
对针对LRP6的各种治疗方法的调查,包括药理学剂,天然化合物和分子疗法.

主要成果:

LRP6在癌症病原和耐药性方面发挥着重要作用.
目前正在研究针对LRP6的多种治疗策略,包括小分子,天然化合物和基于RNA的疗法.
一些针对LRP6的药物已经进入了II期临床试验.

结论:

对于新型癌症疗法来说,LRP6是一个有前途和多方面的目标.
针对LRP6提供了与更广泛的Wnt通路抑制相比的潜在优势.
为了有效治疗癌症,需要对LRP6向剂进行进一步的研究和临床转化.

关键词:

卡尔西波特里奥尔 (PubChem CID: 5288783) 是一种化学物质.癌症治疗治疗癌症治疗基酸 (PubChem CID: 1794427) 是一种化学物质.氨酸 (PubChem CID: 5281607) 吉甘醇 (PubChem CID: 3085362) 这是一种埃奇纳科赛德 (PubChem CID: 5281771) 是一种化物.伊诺西六酸盐 (PubChem CID: 890) 是一种在LRP6中使用LRP6.尼克洛萨米德 (PubChem CID: 4477) 的使用情况潘托普拉 (PubChem CID: 4679) 黄素 (PubChem CID: 969516) 是一种药物,它可以制作剂 (PubChem CID: 135455579) 的使用情况罗特莱林 (PubChem CID: 5281847) 西利比宁 (PubChem CID: 31553) 是一种药物.沙利诺米辛 (PubChem CID: 3085092) 是一种药物.三化物 (PubChem CID: 107985) 是一种在Wnt/β-catenin信号通路中.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...